Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Buparlisib |
INN | buparlisib |
Description | BKM120 is an aminopyridine that is 4-(trifluoromethyl)pyridin-2-amine substituted at position 5 by a 2,6-di(morpholin-4-yl)pyrimidin-4-y group. A selective PI3K inhibitor with anti-tumour properties. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and an antineoplastic agent. It is a member of morpholines, an aminopyrimidine, an aminopyridine and an organofluorine compound. |
Classification | Small molecule |
Drug class | phosphatidylinositol 3-kinase (PI3K) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1 |
PDB | — |
CAS-ID | 1202777-78-3 |
RxCUI | — |
ChEMBL ID | CHEMBL2017974 |
ChEBI ID | 71954 |
PubChem CID | 16654980 |
DrugBank | DB11666 |
UNII ID | 0ZM2Z182GD (ChemIDplus, GSRS) |